Undisclosed anti-Trop-2 x CD3 BisAb
/ iBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 14, 2023
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
(GlobeNewswire)
- "In a recent study involving a humanized mouse model of squamous cell carcinoma, iBio’s TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose."
Preclinical • Oncology • Solid Tumor • Squamous Cell Carcinoma
1 to 1
Of
1
Go to page
1